Search results
Why Novartis Stock Topped the Market on Tuesday
Motley Fool via Yahoo Finance· 6 days agoThe shares did better than the S&P 500 index, which had a relatively good trading session with a 1.2% gain. Double beats in the first quarter In its...
Novartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climb
Investopedia· 6 days agoNovartis beat first-quarter forecasts for profit and sales on rising demand for its blockbuster...
Novartis accused of promoting asthma drug for preterm labor despite brain risk
Reuters· 6 days agoThe five plaintiffs include twins born in 1993 and a man born in 2002, along with their mothers.
Pharma giant Novartis sees shares jump after strong Q1
dpa international via Yahoo Finance· 6 days agoSwiss pharmaceutical giant Novartis saw its shares jump after reporting solid first-quarter profits...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 6 days agoIn February 2024, Novartis announced that it would acquire MorphoSys AG MOR to expand its oncology...
Novartis raises forecasts as top drug sales beat Wall Street estimates
BioPharma Dive via Yahoo Finance· 6 days agoSales of Novartis drugs for heart failure, psoriasis and multiple sclerosis were stronger over the...
Novartis hikes full-year guidance as Q1 results exceed estimates, shares pop By Investing.com
Investing.com· 6 days agoNovartis (NVSEF) shares surged 4.7% in European trading Tuesday after the Swiss pharmaceutical...
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 4 days agoOther drugmakers are following Novartis' lead by snapping up companies focused on the groundbreaking...
Novartis bags paediatric FDA label expansion for Lutathera
Pharmaceutical Technology via Yahoo Finance· 5 days agoPharmaceutical also expanded its radiopharmaceutical pipeline with the acquisition of QSAM...
Novartis Raises Guidance on Profit, Sales Growth
The Wall Street Journal· 6 days agoNovartis lifted its full-year guidance after first-quarter profit and sales rose and beat consensus expectations, boosted by strong sales of key drugs.
